RU-27849, also known as 4,α-methylenetryptamine (4,α-methylene-T), is a serotonin receptor modulator. It can be regarded as a conformationally restricted tricyclic derivative of tryptamine or a structurally simplified derivative of LSD. This molecule was developed during structure–activity relationship (SAR) studies of LSD. It shows affinity for serotonin receptors, including for the serotonin 5-HT1, 5-HT1A, and 5-HT2 receptors (IC50Tooltip half-maximal inhibitory concentration = 267–520 nM, 325–326 nM, and 1,964–2,900 nM, respectively). RU-27849's affinities for serotonin receptors are similar to but lower than those of tryptamine and dimethyltryptamine (DMT). It shows very weak affinity for dopamine receptors and weak associated activity. The 6-methoxy derivative of RU-27849, which is to RU-27849 as 5-methoxytryptamine is to tryptamine, appears to have much higher affinity for serotonin receptors than RU-27849 itself (IC50 ≈ 50 nM). A number of other derivatives also exist, including FHATHBIN (6-hydroxy), RU-28306 (N,N-dimethyl), RU-28251 (N,N-dipropyl), Bay R 1531 (LY-197206; 6-methoxy-N,N-dipropyl), LY-293284 ((4R)-6-acetyl-N,N-dipropyl), and LY-178210 (6-carboxamido-N,N-dipropyl), as well as NDTDI, among others. RU-27849 was first described in the scientific literature by 1981.
See also Partial lysergamide N-DEAOP-NMT CT-5252 Paliclavine 2C-B-5-hemiFLY-α6 4-(2-Aminopropyl)indole (4-API)
References
External links RU-27849 - Isomer Design


